Listed

Kiora Pharmaceuticals Inc: Form 10-Q for the period ended Sep 30, 2015

Filed with the SEC on Nov 12, 2015 and accepted by EDGAR at Nov 12, 2015, 06:09 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2015-07-01 to 2015-09-30$407.6kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2015-01-01 to 2015-09-30$1.3mus-gaap:ResearchAndDevelopmentExpense
Interest expense9 months2015-01-01 to 2015-09-30$1.9mus-gaap:InterestExpense
Net income3 months2015-07-01 to 2015-09-30−$1.4mus-gaap:ProfitLoss
Net income9 months2015-01-01 to 2015-09-30−$5.7mus-gaap:ProfitLoss
Diluted EPS3 months2015-07-01 to 2015-09-30−$0.19us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2015-01-01 to 2015-09-30−$2.46us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2015-01-01 to 2015-09-30−$2.9mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash and equivalentsAt period end2015-09-30$9.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2015-09-30$10.0mus-gaap:AssetsCurrent
Total assetsAt period end2015-09-30$10.1mus-gaap:Assets
Current liabilitiesAt period end2015-09-30$1.4mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2015-09-30$8.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-15-064326. Last ingested by Listed: Nov 12, 2026, 17:43 ET. Listed shows no prices and gives no investment advice.